CORTEX ID SUITE

K141074 · Ge Medical Systems, LLC · KPS · Sep 18, 2014 · Radiology

Device Facts

• Record ID: K141074
• Device Name: CORTEX ID SUITE
• Applicant: Ge Medical Systems, LLC
• Product Code: KPS · Radiology
• Decision Date: Sep 18, 2014
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 892.1200
• Device Class: Class 2
• Attributes: Software as a Medical Device

Intended Use

CortexID software has been developed to aid physicians in the evaluation of patient pathologies via assessment and quantification of PET brain scans. The software aids in the assessment of human brain PET scans enabling automated analysis through quantification of tracer uptake and comparison with the corresponding tracer uptake in normal subjects. The resulting quantification is presented using volumes of interest, voxel-based or 3D stereotactic surface projection maps of the brain. The package allows the user to generate information regarding relative changes in PET-FDG glucose metabolism. CortexID Suite additionally allows the user to generate information in PET brain amyloid load between a subject's images and a normal database, which may be the result of brain neurodegeneration. PET co-registration and fusion display capabilities with CT and MR allow PET findings to be related to brain anatomy and offers visualization of structural abnormalities, which may result from brain injury, trauma, disease or dysfunction, such as subdural hematoma, tumor, stroke, or cerebrovascular disease, etc. CortexID Suite may aid physicians in the image interpretation process of PET studies conducted on patients being evaluated for cognitive impairment, or other causes of cognitive decline, and is an adjunct to other diagnostic evaluations.

Device Story

CortexID Suite is image analysis software for PET brain scans; inputs include PET, CT, and MR image data. Software performs automated quantification of tracer uptake (FDG and beta-amyloid) by registering images to a standard template space and comparing intensity values against normal subject databases. Outputs include volumes of interest (VOI), voxel-based maps, and 3D stereotactic surface projection (SSP) maps. Used in clinical settings by physicians to aid in interpreting studies for cognitive impairment or structural brain abnormalities. Features include PET-MR/CT fusion, longitudinal analysis, and automated reorientation. Provides clinicians with quantitative data to support diagnostic decision-making regarding neurodegeneration or other pathologies.

Clinical Evidence

No clinical data. Substantial equivalence supported by bench testing, verification, and validation of software performance. Clinical studies were not required as the modification involves analysis of new PET image contrast agents and does not significantly affect clinical safety or performance.

Technological Characteristics

Software-based image analysis platform. Complies with NEMA PS 3.1-3.20 (DICOM) standards. Features automated reorientation, standardization, and registration algorithms. Supports PET-MR and PET-CT fusion. Operates on AW VolumeShare 5 workstation. Development followed rigorous quality assurance including risk analysis, design reviews, and system verification/performance testing.

Indications for Use

Indicated for patients undergoing brain PET scans for evaluation of cognitive impairment or decline, or structural abnormalities (e.g., tumor, stroke, trauma, neurodegeneration). Used as an adjunct to other diagnostic evaluations.

Regulatory Classification

Identification

An emission computed tomography system is a device intended to detect the location and distribution of gamma ray- and positron-emitting radionuclides in the body and produce cross-sectional images through computer reconstruction of the data. This generic type of device may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories.

Predicate Devices

• CortexID (K062393)

Reference Devices

• AW VolumeShare 5 workstation (K110834)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular, with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the top half of the circle. The bottom half of the circle contains a stylized image of three human profiles facing to the right. The profiles are connected by a flowing line.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

September 19, 2014

GE Medical Systems, LLC % Mr. David Duersteler Regulatory Affairs Leader 3000 North Grandview Blvd. WAUKESHA WI 53188

Re: K141074 Trade/Device Name: CortexID Suite Regulation Number: 21 CFR 892.1200 Regulation Name: Emission computed tomography system Regulatory Class: II Product Code: KPS Dated: September 12, 2014 Received: September 15, 2014

Dear Mr. Duersteler:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

Michael D. O'Hara

for

Janine M. Morris Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

### Indications for Use

510(k) Number (if known) K141074

Device Name CortexID Suite

#### Indications for Use (Describe)

CortexID software has been developed to aid physicians in the evaluation of patient pathologies via assessment and quantification of PET brain scans.

The software aids in the assessment of human brain PET scans enabling automated analysis through guantification of tracer uptake and comparison with the corresponding tracer uptake in normal subjects. The resulting quantification is presented using volumes of interest, voxel-based or 3D stereotactic surface projection maps of the brain. The package allows the user to generate information regarding relative changes in PET-FDG glucose metabolism.

CortexID Suite additionally allows the user to generate information in PET brain amyloid load between a subject's images and a normal database, which may be the result of brain neurodegeneration.

PET co-registration and fusion display capabilities with CT and MR allow PET findings to be related to brain anatomy and offers visualization of structural abnormalities, which may result from brain injury, trauma, disease or dysfunction, such as subdural hematoma, tumor, stroke, or cerebrovascular disease, etc.

CortexID Suite may aid physicians in the image interpretation process of PET studies conducted on patients being evaluated for cognitive impairment, or other causes of cognitive decline, and is an adjunct to other diagnostic evaluations. Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

## PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

#### FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

{3}------------------------------------------------

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

Image /page/4/Picture/1 description: The image shows the logo for General Electric (GE). The logo is a blue circle with the letters "GE" in white inside. The circle is surrounded by a white border with a stylized design that looks like water droplets. The logo is simple and recognizable, and it is often used to represent the company's products and services.

# 510(k) Summary

In accordance with 21 CFR 807.92 the following summary of information is provided:

| Date: | April 23, 2014 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Submitter: | GE Medical Systems, LLC |
| | 3000 North Grandview Blvd.<br>Waukesha, WI 53188, USA |
| Primary Contact Person: | Peter Uhlir |
| | Regulatory Affairs Leader |
| | Tel: [phone]<br>Fax: [phone] |
| Secondary Contact<br>Person: | Jeme Wallace<br>Regulatory Affairs Director<br>GE Healthcare<br>Tel: [phone]<br>Fax: [phone] |
| Device Trade Name: | CortexID Suite |
| Common/Usual Name: | CortexID Suite |
| Classification Names: | 21CFR 892.1200, Radiology |
| Product Code: | KPS |
| Predicate Device(s): | K062393 - CortexID (originally called GE Vantage PET Neuro) |
| Device Description: | CortexID, image analysis software, has been developed to aid<br>clinicians in the assessment and quantification of pathologies<br>derived from PET scans. The software enables the display, co-<br>registration, and fusion of PET images with those from other<br>modalities. It enables automated quantitative and statistical<br>analysis of tracer uptake by registration to a standard template<br>space and comparing intensity values. Additionally, CortexID<br>assists with comparison of the activity in defined brain regions<br>of individual scans relative to normal activity values as found in<br>normal subjects. Quantification is presented using volumes of<br>interest, voxel-based or 3D stereotactic surface projection maps<br>of the brain. |
| Key features of the CortexID Suite include: | |
| a. Integrated platform for FDG and Beta Amyloid analysis | |
| b. PET-MR and PET-CT registration and fusion | |
| c. Automatic reorientation and standardization | |
| d. 3D SSP, Voxel based images and VOI statistics | |
| e. Comparison with normals databases | |
| f. Longitudinal Analysis | |
| g. Q.Check | |
| h. Summing input dynamic PET scan | |
| i. Exam Summary (integrated report) | |
| j. Easy Export | |
| k. Multiple Reference Regions | |
| l. Reoreintation | |
| m. Region Overlay | |
| n. Fully Customizable Interface | |
| o. Preset Presentations | |
| p. MR Template Image | |
| The CortexID Suite is also made available as a standalone post processing application on the AW VolumeShare 5 workstation (K110834) that hosts advanced image processing applications. | |
| Indications for Use /<br>Intended Use: | CortexID software has been developed to aid physicians in the evaluation of patient pathologies via assessment and quantification of PET brain scans. |
| | The software aids in the assessment of human brain PET scans enabling automated analysis through quantification of tracer uptake and comparison with the corresponding tracer uptake in normal subjects. The resulting quantification is presented using volumes of interest, voxel-based or 3D stereotactic surface projection maps of the brain. The package allows the user to generate information regarding relative changes in PET-FDG glucose metabolism. |
| | CortexID Suite additionally allows the user to generate information in PET brain amyloid load between a subject's images and a normal database, which may be the result of brain neurodegeneration. |
| | PET co-registration and fusion display capabilities with CT and |
| | MR allow PET findings to be related to brain anatomy and offers<br>visualization of structural abnormalities, which may result from<br>brain injury, trauma, disorder, disease or dysfunction, such as<br>subdural hematoma, tumor, stroke, or cerebrovascular disease,<br>etc.<br><br>CortexID Suite may aid physicians in the image interpretation<br>process of PET studies conducted on patients being evaluated<br>for cognitive impairment, or other causes of cognitive decline,<br>and is an adjunct to other diagnostic evaluations. |
| Technology: | The CortexID Suite software employs the same fundamental<br>scientific technology as its predicate device. |
| Determination of<br>Substantial Equivalence: | Summary of Non-Clinical Tests:<br>The CortexID Suite software complies with NEMA PS 3.1 - 3.20<br>(2011) Digital Imaging and Communications in Medicine (DICOM)<br>Set (Radiology) standard.<br><br>CortexID Suite employs the same fundamental scientific<br>technology as its predicate device, CortexID. CortexID Suite uses<br>the equivalent DICOM image data input requirements. It has<br>equivalent display, formatting, archiving and visualization<br>technologies compared to the predicate device. CortexID Suite<br>utilizes essentially the same methodology to quantify and<br>assess uptake of FDG and beta amyloid tracers. The information<br>is presented using volumes of interest, voxel-based or 3D<br>stereotactic surface projection maps of the brain. CortexID Suite<br>utilizes existing PET & CT co-registration and fusion<br>technologies and provides for PET & MR co-registration and<br>fusion capabilities. Thorough testing of these capabilities has<br>not raised any safety or effectiveness issues.<br><br>The following quality assurance measures were applied to the<br>development of the system:<br>■ Risk Analysis<br>■ Requirements Reviews<br>■ Design Reviews<br>■ Integration testing (System verification)<br>■ Performance testing (Bench testing, verification)<br>■ Safety testing (Verification) |
| | Summary of Clinical tests:<br>The subject of this premarket submission, CortexID Suite<br>software did not require clinical studies to support substantial<br>equivalence since it introduces analysis of new PET image<br>contrast agents only. The clinical utility for the analysis of the<br>new image processing has not been studied since modification |
| | does not significantly affect the clinical safety and performance.<br>The substantial equivalence determination is based on the<br>software documentation for a MODERATE level of concern<br>device. |
| Conclusion: | GE Healthcare considers the CortexID Suite software<br>application to be as safe, as effective, and performance is<br>substantially equivalent to the predicate device. |

{5}------------------------------------------------

Image /page/5/Picture/1 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'GE' in a stylized, cursive font, enclosed within a blue circle. The circle has a series of white, curved lines around it, resembling water droplets or stylized waves, giving the logo a dynamic and recognizable appearance.

{6}------------------------------------------------

Image /page/6/Picture/1 description: The image shows the logo for General Electric (GE). The logo consists of the letters 'GE' written in a stylized script, enclosed within a blue circle. There are small, white, teardrop-shaped elements surrounding the circle, giving it a dynamic and recognizable appearance. The logo is simple, yet distinctive, and is widely recognized as the symbol of the General Electric company.

{7}------------------------------------------------

Image /page/7/Picture/1 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'GE' in a stylized, cursive font, enclosed within a blue circle. The circle has a series of white, curved lines around it, resembling water droplets or stylized waves, which gives the logo a dynamic and modern appearance.